Shire gets FDA approval to market ADHD drug for adults in U.S.

08/13/2004 | Scotsman (Edinburgh), The

Scotland's Shire Pharmaceuticals announced it has received approval from the FDA for the sale of its Adderall XR attention deficit hyperactivity disorder treatment for adults in the U.S. The company already has approval to market the drug for treatment of children and says it will begin marketing to adults immediately. Adderall XR is the most-prescribed brand for ADHD treatment in the states, and Shire says sales to adults could be double that for children.

View Full Article in:

Scotsman (Edinburgh), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY